[Remote] Senior Scientist, Clinical Pharmacology at Abata Therapeutics

Remote

Abata Therapeutics Logo
Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, PharmaceuticalsIndustries

Skills

Key technologies and capabilities for this role

Pharmacokinetic modelingNon-compartmental analysisTranslational researchExposure/response relationshipsClinical development plans

Questions & Answers

Common questions about this position

What is the work location or remote policy for this role?

The position offers remote work throughout the United States or hybrid options in Menlo Park, CA or Waltham, MA.

What are the key responsibilities of this Clinical Scientist role?

Key responsibilities include pharmacokinetic modeling, analyzing clinical PK data using non-compartmental analysis, engaging in translational research, exploring exposure/response relationships, and authoring clinical pharmacology sections of study documents.

What skills or experience are required for this position?

Proficiency in pharmacokinetic modeling, non-compartmental analysis (NCA), population PK/PD, model-informed drug development (MIDD), and translational research is essential, along with experience in clinical study protocols and vendor management.

What is the company culture like at Oruka Therapeutics?

Oruka seeks top talent passionate about making a difference and contributing to an engaged, inclusive, and positive company culture as they build their core team.

What makes a strong candidate for this Senior Scientist role?

Strong candidates are passionate about impactful work in therapeutics, have expertise in clinical pharmacology including PK/PD modeling and analysis, and are eager to contribute to team culture while driving rapid clinical development.

Is there a salary range or compensation information provided?

This information is not specified in the job description.

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters
2021Year Founded
$184.8MTotal Funding
EARLY_VCCompany Stage
BiotechnologyIndustries
11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.
Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.
Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.
Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.
Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.
FDA's accelerated approval pathways may expedite Abata's clinical trials.
Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI